Topics

Stevanato Group, Haselmeier Ink Exclusive Agreement in Diabetes Care

05:03 EDT 7 Oct 2019 | Contract Pharma

Licenses Axis-D Pen-injector technology and IP to support diabetes applications

Original Article: Stevanato Group, Haselmeier Ink Exclusive Agreement in Diabetes Care

NEXT ARTICLE

More From BioPortfolio on "Stevanato Group, Haselmeier Ink Exclusive Agreement in Diabetes Care"

Quick Search

Relevant Topic

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...